BHIVA statements on HIV and COVID-19

Simon Collins, HIV i-Base

Over the last few weeks, BHIVA have posted eight online statements about COVID-19.

Although summarised below, all BHIVA statements are published on the BHIVA website where future updates will be added.

BHIVA statement on COVID-19 and advice for the extremely vulnerable (25 March 2020)

This statement updates advice based on new information from the UK government about social physical distancing.

BHIVA statement on management of a pregnant woman living with HIV and infant testing during Coronavirus (COVID-19) (25 March 2020)

This statement refers to minimal HIV monitoring for HIV positive women who are pregnant during the current coronavirus crisis and for HIV monitoring of the infant.

Comment from BHIVA on Social Distancing and Shielding to (23 March 2020)

This information looks at how to protect against COVID-19 depending on your CD4 count. Having a CD4 count less than 50 cells/mm3 makes someone “extremely vulnerable”. This means following advice for “shielding” – basically isolating at home for three months with support to get supplies and food.

  1. People with a CD4 count <50 or opportunistic illness in last 6 months: follow shielding advice for extremely vulnerable. This includes avoiding face-to-face contact for 12 weeks – and will need support to do this.
  2. People with CD4 <200, detectable viral load or not on ART: follow social distancing advice very closely.
  3. People with CD4 >200 and undetectable on ART: follow general population advice (ie social physical distancing).

EACS & BHIVA Statement on risk of COVID-19 for people living with HIV (PLWH) (20 MARCH 2020)

This joint statement is to emphasise consistent expert opinion across Europe that HIV is not an additional risk for COVID-19 if someone is on effective ART. Having a CD4 count below 200 cells/mm3 or not being on ART is likely to increase the risk though.

There is no evidence to support any benefit from HIV meds against coronavirus. Neither ART nor PrEP will protect against or treat coronavirus.

Liverpool University have published a new website ( for the experimental drugs being studied to treat COVID-19.

Coronavirus (COVID-19) and HIV – Responses to common questions (19 March 2020)

This update answers eight common questions about COVID-19 for HIV positive people. It includes that HIV drugs are not effective against coronavirus, to continue taking ART as usual, and that there are no problems with supplies of HIV meds. Self-distancing is important (not self-isolation), as is following advice for general population to reduce risk.

BHIVA statement on self-isolation/distancing (17 March 2020)

This update mainly refers people to the UK Government website ( to explain how to respond to the advice to limit social interactions.

BHIVA update on coronavirus (COVID-19) and HIV (13 March 2020)

Following CROI 2020, there continues to be no evidence that people with HIV are at higher risk of COVID-19, or severe disease if affected, and no evidence regarding the impact of viral load or CD4 on either of these.

You may have read that the HIV drug lopinavir/ritonavir (Kaletra) is being studied as a possible treatment for COVID-19 but this is based on very limited evidence for similar viruses. So far there is no good evidence that lopinavir/ritonavir is beneficial, and no evidence that other HIV drugs will help. For anyone taking HIV drugs for treatment or prevention, we recommend continuing to take treatment as recommended, and not increasing the dose or switching to other medications unless otherwise indicated.

There has been one case report published of a man with HIV and diabetes who was hospitalised with COVID-19, treated with lopinavir/ritonavir and who subsequently recovered. However, this provides no further information on the impact of either HIV per se, or lopinavir/ritonavir, on COVID-19:

BHIVA continue to recommend following national advice as provided here and encouraging people with HIV to ensure they have had their flu and appropriate pneumococcal vaccines (as per BHIVA vaccine guidelines.) We also advise that patients have at least 30-days medication available and sufficient supply to allow for possible travel restrictions or quarantine, if they are planning to leave the UK.

Individual organisations will be making their own contingency plans, and most non-urgent services are being asked to minimise face-to-face appointments. As the set-up and capacity of services will vary significantly, we cannot give specific recommendations, but if people have examples of good practice they wish to share, BHIVA can facilitate this. Sensible steps include updating your website if you have one, using out-of-office replies to direct patients to appropriate advice and ensuring all patient-facing staff are aware of the latest national information and guidance.

We advise against prescribing longer than usual medication supplies as stocks can be fragile at any time. Please also note, for those of you based in England, NHSE have instructed us to avoid signing new people up to Homecare as they need to focus on maintaining current capacity.

BHIVA recommendations for COVID-19 (27 February 2020)

  • Following the regularly updated advice from Public Health England, Health Protection Scotland, Public Health Wales, the Department of Health Northern Ireland and the Health Service Executive Ireland.
  • Ensuring people with HIV have received influenza and pneumococcal vaccination in line with BHIVA vaccine guidelines.

BHIVA guidelines for pneumococcal and flu vaccines.

Links to other websites are current at date of posting but not maintained.